Calidi Biotherapeutics Inc (AMEX:CLDI) shares, rose in value on Thursday, July 10, with the stock price up by 42.57% to the previous day’s close as strong demand from buyers drove the stock to $1.0.
Actively observing the price movement in the last trading, the stock closed the session at $0.7, falling within a range of $0.66 and $1.1. The value of beta (5-year monthly) was 1.06. Referring to stock’s 52-week performance, its high was $3.89, and the low was $0.20. On the whole, CLDI has fluctuated by 204.27% over the past month.
With the market capitalization of Calidi Biotherapeutics Inc currently standing at about $34.45 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-14.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CLDI’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of CLDI currently trading nearly 198.89% and 162.48% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 89.45, while the 7-day volatility ratio is showing 56.19% which for the 30-day chart, stands at 23.01%. Furthermore, Calidi Biotherapeutics Inc (CLDI)’s beta value is 0.96.
A comparison of Calidi Biotherapeutics Inc (CLDI) with its peers suggests the former has fared considerably weaker in the market. CLDI showed an intraday change of 42.57% in last session, and over the past year, it shrunk by -13.22%%.
Data on historical trading for Calidi Biotherapeutics Inc (AMEX:CLDI) indicates that the trading volumes over the past 10 days have averaged 78.88 and over the past 3 months, they’ve averaged 11.71 million. According to company’s latest data on outstanding shares, there are 34.52 million shares outstanding.
Nearly 6.57% of Calidi Biotherapeutics Inc’s shares belong to company insiders and institutional investors own 15.78% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.37 million shares as on 2025-06-13, resulting in a short ratio of 0.74. According to the data, the short interest in Calidi Biotherapeutics Inc (CLDI) stood at 126.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 0.27 million. The stock has fallen by -38.43% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CLDI stock heading into the next quarter.
